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PURPOSE. Smith-Magenis syndrome (SMS) causes sleep disturbance that is related to an
abnormal melatonin profile. It is not clear how the genomic disorder leads to a disturbed
synchronization of the sleep/wake rhythm in SMS patients. To evaluate the integrity of the
intrinsically photosensitive retinal ganglion cell (ipRGC)/melanopsin system, the transducers
of the light-inhibitory effect on pineal melatonin synthesis, we recorded pupillary light
responses (PLR) in SMS patients.
METHODS. Subjects were SMS patients (n ¼ 5), with molecular diagnosis and melatonin levels
measured for 24 hours and healthy controls (n ¼ 4). Visual stimuli were 1-second red light
flashes (640 nm; insignificant direct ipRGC activation), followed by a 470-nm blue light, near
the melanopsin peak absorption region (direct ipRGC activation). Blue flashes produce a
sustained pupillary constriction (ipRGC driven) followed by baseline return, while red flashes
produce faster recovery.
RESULTS. Pupillary light responses to 640-nm red flash were normal in SMS patients. In
response to 470-nm blue flash, SMS patients had altered sustained responses shown by faster
recovery to baseline. SMS patients showed impairment in the expected melatonin production
suppression during the day, confirming previous reports.
CONCLUSIONS. SMS patients show dysfunction in the sustained component of the PLR to blue
light. It could explain their well-known abnormal melatonin profile and elevated circulating
melatonin levels during the day. Synchronization of daily melatonin profile and its
photoinhibition are dependent on the activation of melanopsin. This retinal dysfunction
might be related to a deficit in melanopsin-based photoreception, but a deficit in rod function
is also possible.
Keywords: retina, ipRGC, melanopsin, retinohypothalamic pathway, pupillary light reflex,
pupillometry, Smith-Magenis syndrome
Smith-Magenis syndrome (SMS) is a genomic disorderassociated with a common deletion interval of 3.5 to 5.0
Mb of an interstitial region of chromosome 17, band p11.2.
Among the several genes included in this region, retinoic acid
induced 1 (RAI1) gene atypical deletions and heterozygous
point mutations are associated with the phenotype.1–4 The
clinical phenotype includes craniofacial anomalies, intellectual
disability, self-injurious and aggressive behavior, as well as
severe sleep disturbances, described as short sleep, nocturnal
awakenings, difficulty falling asleep at night, and daytime
sleepiness.5,6 Sleep disturbances in SMS patients are usually
correlated with an abnormal melatonin profile, with high
melatonin levels during the day and low levels at night.7–9 This
behavior of melatonin production, highly frequent in SMS
patients, is not expected since melatonin production is blocked
by environmental light, especially light in the blue spectral
range.10,11
Pineal melatonin is produced under strict control of the
circadian timing system, and its production is synchronized by
the light/dark environmental cycle. Melatonin is most abun-
dantly synthesized during the dark phase regardless of the
behavioral distribution of the daily activity of the considered
mammalian species.10 Elevated levels of circulating melatonin
are associated with the dark phase of the light/dark cycle
provided there is no light in the environment, since light during
the night inhibits pineal melatonin synthesis, mainly through
the activation of a highly specialized retinal melanopsin
system.11–17
The neural system that mediates light entrainment of
circadian rhythms, melatonin photoinhibition, and pupillary
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responses to light, besides several other nonimage-forming
visual functions, originates in the intrinsically photosensitive
retinal ganglion cells (ipRGCs). These retinal ganglion cells
express a photopigment called melanopsin that enables them
to be directly activated by light.11–14,17–20 The ipRGC axons
leave the retina as part of the optic nerve and project to central
structures that regulate the circadian rhythm such as the
suprachiasmatic nucleus, the subparaventricular zone, the
ventrolateral preoptic area, and the intergeniculate leaflet.15,21
It is well established that both exogeneous and endoge-
neous mechanisms might affect the circadian rhythm genera-
tion and/or synchronization; therefore, the alteration of one or
both mechanisms might cause perturbations of the circadian
internal order (chronodisruption),22 leading to sleep distur-
bances.
The spectral sensitivity of melanopsin peaks in the blue
spectral range, at ~480 nm.23 The ipRGCs control the
pupillary response to light. The initial transient peak constric-
tion in response to light is attributed to ipRCGs stimulated by
rods and cones, while the sustained component of the
pupillary response to light has been attributed to the direct
activation of the ipRGCs by the light.24,25
The integrity of the retinal melanopsin system may be
assessed by the pupillary light reflex (PLR), which measures
the constriction and subsequent dilation of the pupil to a
change in light stimulation. The PLR to flashes of red light
(which falls away from the peak of the melanopsin absorption
spectrum) and of blue light, that maximally activates ipRGCs,
provide a measure of the melanopsin contribution to the PLR.
Thus, the PLR is an important noninvasive tool that allows the
measurement of the functionality of the retinal melanopsin
system.26–30
We speculate that the SMS patients’ sleep disorders might
be the result of a dysfunctional ipRGC/melanopsin retinal
system, since their sleep/wake disturbances are usually
associated with an abnormal melatonin production profile,
displaced to daytime, and resistant to photoinhibition. This
assumption finds support in several demonstrations of the
association between sleep disturbances and alteration in
ipRGC activity assessed through the PLR27–31 and in the
demonstration that the lack of one RAI1 allele (the primary
gene responsible for most features of SMS, including the
inverted circadian rhythm of melatonin32,33) affects the
nonvisual light-signaling dependent behavior.34
In order to evaluate the functionality of this retinal system,
we tested SMS patients using the PLR protocol,26 particularly
its sustained component that is controlled by the ipRGC/
melanopsin system.24,25
MATERIALS AND METHODS
Participants
PLRs were recorded from five SMS patients (aged 7 to 26 years
old; average ¼ 13 6 8 years old) and four healthy volunteers
(all subjects were 17 years old). SMS patients were selected in
the Child Neurology Outpatient Clinic of the Clinics Hospital
of the University of Sa˜o Paulo. All parents received appropriate
information about the nature and possible consequences of the
study and signed a written informed consent. The research
followed the tenets of the Declaration of Helsinki and was
approved by the Ethics Committees of the Institute of
Psychology (CAAE 56608616.1.0000.5561) and of the Clinics
Hospital of the University of Sa˜o Paulo (CEP 16761). All
subjects underwent complete ophthalmologic examination.
Inclusion criteria for SMS patients were defined as molecular
diagnosis, with 17p11.2 deletion demonstrated with MLPA
(multiplex ligation-dependent probe amplification) technique,
normal ophthalmologic examination, and ability to understand
the task. For control subjects the exclusion criteria were
presence of ophthalmologic or central nervous system
diseases. Table 1 provides the SMS subjects’ demographic data.
Sleep/wake behavior was recorded for 1 month with sleep logs
for all SMS subjects.
Pupillary Light Response Protocol
PLR was measured monocularly at the stimulated eye while the
other eye was covered. PLR was measured with the RETiport
system with a light stimulator (Super Color Ganzfeld Q450SC;
Roland Consult, Brandenburg, Germany). A dark adaptation
period of 10 minutes preceded the light stimulation. PLRs were
TABLE 1. Demographic and Clinical Data of the Subjects
Subjects Age, y Sex Molecular Diagnosis Clinical Symptoms Treatment
SMS 1 7 M 3.7 Mb interstitial deletion in
17p11.2
Development delay, sleep
disturbance, irritability,
cardiopathy
Risperidone, fluoxetine,
imipramine, melatonin
SMS 2 14 F 3.7 Mb interstitial deletion in
17p11.2
Development delay, irritability Carbamazepine, risperidone
SMS 3 26 F 3.7 Mb deletion in 17p11.2 Development delay, sleep
disturbance, neurogenic
bladder, dysmorphic features
Amlodipine
SMS 4 10 F Interstitial deletion in 17p11.2 Development delay, sleep
disturbance, compulsive
feeding
Risperidone, topiramate,
imipramine, melatonin,
metformin
SMS 5 7 M Interstitial deletion in 17p11.2 Development delay Risperidone, sertraline
Average 12.8
Standard deviation 7.9
Control 1 17 F – – –
Control 2 17 F – – –
Control 3 17 F – – –
Control 4 17 F – – –
Average 17.0
Standard deviation 0.0
Mb, megabase.
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recorded in response to 1-second light flashes using two
different wavelengths: red light (peak wavelength 6 full width
at half maximum: 638 6 9 nm), which falls away from the peak
of the melanopsin absorption spectrum (insignificant direct
activation of the ipRGCs), followed by blue light (469 6 11
nm), which is close to the peak absorption of melanopsin
(direct activation of the ipRGCs). A 2-minute interval between
the flashes was observed. Photopic luminance was set to 100
candelas per square meter (cd/m2) for both red and blue lights.
One luminance level was used in order to make the protocol
the briefest possible, since the behavioral disturbances of the
patients did not allow us to perform extensive measurements.
The choice of 100 cd\m2 was based on a previous study of Park
et al.,26 showing clear differences between the sustained
responses to blue and red light flashes at this luminance level.
In addition, previous studies from our group showed that
luminances higher than 100 cd/m2 do not significantly change
the magnitude of the sustained response.27,29,30 Figure 1 is a
diagram of the protocol, showing the time course of the
measurements, parameters of the light flashes, and the
intervals between them. Recordings were repeated if blink
artifacts coincided with the peak response or happened to
occur between 5 and 7 seconds after flash presentation. If
repetition was necessary, the protocol was performed again on
another day.
Urinary 6-Sulfatoxymelatonin
Urinary 6-sulfatoxymelatonin levels were assessed in the SMS
patients and matched controls using ELISA (IBL International,
Hamburg, Germany), according to the manufacturer’s instruc-
tions. Urine samples were collected from all subjects during 24
hours in three different containers, according to the corre-
sponding period: morning (7:00 AM to 1:00 PM), afternoon
(1:00 PM to 7:00 PM), and night (7:00 PM to 7:00 AM). The
final analysis was done computing day (7:00 AM to 7:00 PM,
morning þ afternoon) versus night (7:00 PM to 7:00 AM) in
both SMS patients and control subjects, and 6-sulfatoxymela-
tonin was measured as a day and night percentage of the 24-
hour excreted load. Samples were homogenized, had their
volumes assessed, and were kept under 808C prior to the
assay.
Data Analysis
We analyzed the PLR peak response (time and amplitude of the
smallest diameter after the light stimulation) and the median
amplitude of the sustained component (average amplitudes
between 5 and 7 seconds after the flash onset) to both red and
blue lights. The sustained response of the PLR had previously
been estimated using a longer flash presentation as the average
pupil constriction between 15 and 30 seconds after light
offset.24 Here we followed parameters previously standardized
for a 1-second flash presentation: the sustained pupil response
was measured at 6 seconds after flash offset.26 However, we
used a broader window (5–7 seconds) in order to avoid
artifacts that could influence the results if only 1 second was
considered to calculate this component. The urinary 6-
sulfatoxymelatonin values are expressed in percentage of the
24-hour mean for each patient, and the mean 6 standard error
of mean (n¼ 5 patients and n¼ 4 controls) for each period of
time was analyzed by 1-way ANOVA.
RESULTS
Sleep onset for SMS patients ranged from 8 PM to 11 PM and
wake-up time varied from 4 AM to 8 AM, with sleep onset
being stable for each patient and more variability observed for
wake-up time. Diurnal naps lasting approximately 1 hour were
frequently reported for patients 2, 3, and 4, occurring at 8 AM
for patient 2 (this patient usually wakes up at 5 AM), at 2 PM
for patient 3, and at 8 AM and 2 PM for patient 4. The other
two patients had sporadic diurnal naps. All patients, except
subject 1, reported one night awakening, usually lasting
approximately 30 minutes, in the beginning or in the end of
the main sleep episode, but families were already instructed to
keep lights off in these moments.
As shown in Figure 2, control subjects showed the
expected daily 6-sulfatoxymelatonin profile, with higher levels
during the night and lower levels during the day. On the
contrary, SMS patients presented the previously described
inversion,4 with higher percentage during the day and lower
percentage during the night.
PLRs from a representative control (upper panel) are shown
in Figure 3 for both parameters analyzed: peak response and
sustained component. As previously mentioned, the response
to a blue light flash shows a conspicuous sustained compo-
nent, which is attributed to the function of the ipRGCs.
The PLRs of the SMS patients (n¼ 5 for the red flash, and n
¼ 4 for the blue flash) are shown in Figure 3 (lower panel)
together with the average responses of the controls (thicker
traces) and the respective standard errors (shaded area). For
the red flash, the responses of the SMS patients overlap the
average (6SE) response of the control subjects. On the other
hand, SMS patients showed altered sustained components of
the PLR for the blue flash compared to control subjects.
FIGURE 1. The PLR protocol started with 10 minutes of dark
adaptation followed by a 1-second red flash. After 2 minutes of dark
adaptation, the blue flash was presented. Pupil size was recorded
during 1 minute, beginning 5 seconds before each light flash
presentation. FIGURE 2. SMS patients’ (N ¼ 5) and controls’ (N ¼ 4) urinary 6-
sulfatoxymelatonin levels during the day (7:00 AM to 7:00 PM) and at
night (7:00 PM to 7:00 AM). Values are expressed as percentage of the
24-hour excreted load (lg/h).
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The peak constriction of the pupil was expressed with
reference to the normalized baseline pupil diameter. For the
red flash stimulation, this value was 0.53 6 0.07 for the control
group and 0.56 6 0.12 for the SMS patients. The peak
response of the control subjects occurred 1.40 6 0.12 and the
SMS patients 1.52 6 0.32 seconds after the flash onset. The
sustained response after the red flash stimulation was 0.90 6
0.05 for the control subjects and 0.89 6 0.06 for the SMS
patients.
For the blue flash, the normalized pupil diameter at the
peak constriction was 0.47 6 0.04 for the control subjects and
0.48 6 0.04 for the SMS patients. The time to reach the peak
was 2.30 6 0.70 seconds after the flash onset for the control
group and 1.88 6 0.30 seconds for the SMS patients. The
sustained response (normalized pupil diameter between 5 and
7 seconds after the flash) was 0.51 6 0.04 for the control
group and 0.64 6 0.03 for the SMS patients.
Figure 4 shows the average 6 standard deviation of the
control subjects and the SMS patients for the three parameters
analyzed: peak constriction (left graphs), time to peak (middle
graphs), and sustained response (right graphs) for the red flash
(upper graphs) and for the blue flash (lower graphs). Table 2
shows the individual results for the red (left column) and for
the blue (right column) flash.
DISCUSSION
We showed, using the PLR, that SMS patients have a decreased
ipRGCs activation compared to healthy subjects. This was
indicated by their sustained response to a 469-nm blue light
stimulation, showing a faster recovery toward the baseline
pupil diameter in the dark. These new findings point to an
abnormal functioning of the retinal–melanopsin system and
FIGURE 3. Normalized pupil diameter of a representative control for the red (left) and for the blue (right) flash presentation (upper panel). Lower
panel shows the average responses of control subjects in thick traces (n¼ 4 eyes) and individual responses of the SMS patients (n¼ 5 for the red
flash, and n¼4 for the blue flash) in thin traces. The shaded area is the standard error of the control group. Left graph shows the responses to the
red flash and right graph to the blue flash. The black dotted lines represent the base line recording prior to flash presentation. PLR recorded from
the 638-nm red light stimulation (left) and from the 469-nm blue light stimulation (right). Components analyzed: peak response (minimum
amplitude of normalized pupil diameter and time to peak after the flash) and sustained response. The sustained response was calculated from the
average normalized pupil diameter between 5 and 7 seconds from time 0, which was the flash onset. Flashes were presented for 1 second, 5
seconds after recording started (red and blue dotted lines).
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might explain, at least partially, the anomaly of the daily
melatonin profile in SMS patients.
The altered melanopsin response of our patients, evidenced
in their PLR changes to blue light, might be associated with
their sleep disturbances, since the ipRGCs, or melanopsin-
expressing RGCs, project both to the suprachiasmatic nucleus
(SCN) of the hypothalamus, involved in the regulation of the
circadian rhythm, and to the olivary pretectal nucleus (OPN),
involved in the PLR, as well as other nonvisual areas.21,35,36
Previous studies have attributed a reduction in the sustained
response of the PLR to a decreased activation of the
ipRGCs,26–30 although it is still not known whether the same
type of ipRGCs in the human retina projects to both the SCN
and the OPN.37 This reduction in response might be present in
other functions mediated by the ipRGCs and has been linked
by several authors to a disruption in sleeping pattern.28–31 On
the other hand, patients with neuroretinal disorders that seem
to spare the ipRGCs, such as Leber’s hereditary optics
neuropathy, have not shown signals of sleep disturbances.27
Reduced scotopic ERG responses, with no anatomic or
molecular retinal alteration, were found in the RAI1þ/, the
mouse model of SMS, indicating a possible photoreceptoral
cause of light entrainment dysfunction.34 Considering that rods
also send sustained signals to the ipRGCs, which contribute to
the PLR, and that rod responses become increasingly
prolonged as the stimulus intensity increases,38 a deficit in
rod function is also possible.
Park et al.26 have shown that in human PLRs recorded from
dark-adapted eyes using low stimulus intensity, the sustained
components to red and blue light were quite similar. The
sustained pupil responses became different between red (640 6
10 nm) and blue (467 6 17 nm) light only above appoximately
1 log cd/m2. In the present study, we used similar wavelengths
(red light¼ 638 6 9 nm, and blue light¼ 469 6 11 nm) used by
Park et al.,26 and the luminance of the blue flash (100 cd/m2)
was much above 1 log cd/m2. Moreover, measurements
performed in humans and nonhuman primates24 support the
hypothesis that the sustained constriction of the pupil after blue
light offset depends on ipRGCs/melanopsin activation.
Considering the activation of the photoreceptors by the
blue flash, one might also consider that other cellular signals,
such as ON-bipolar and amacrine cells, are involved in the
FIGURE 4. Average 6 1 SD of control subjects and SMS patients for the three parameters analyzed: peak response amplitude as normalized pupil
diameter (left graphs), time to peak in seconds (middle graphs), and sustained response (right graphs) for the red flash (upper graphs) and for the
blue flash (lower graphs).
TABLE 2. Individual Results of the Red (Left Column) and the Blue (Right Column) PLRs
Eye
Peak Response: Normalized Ø/Time, s Sustained Response*
Red Blue Red Blue
SMS 1 OS 0.76/2.0 0.53/2.3 0.98 0.68
SMS 2 OS 0.50/1.5 0.46/1.8 0.91 0.62
SMS 3 OS 0.52/1.5 0.45/1.8 0.85 0.63
SMS 4 OD 0.55/1.5 0.48/1.6 0.85 0.61
SMS 5† OD 0.47/1.1 – 0.85 –
Average 0.56/1.52 0.48/1.88 0.89 0.64
Standard deviation 0.12/0.32 0.04/0.30 0.06 0.03
Control 1 OD 0.49/1.3 0.46/1.5 0.86 0.47
Control 2 OD 0.46/1.3 0.43/1.5 0.86 0.57
Control 3 OS 0.55/1.5 0.48/2.6 0.95 0.49
Control 4 OS 0.62/1.5 0.52/2.8 0.92 0.52
Average 0.53/1.40 0.47/2.30 0.90 0.51
Standard deviation 0.07/0.12 0.04/0.70 0.05 0.04
Ø, diameter.
* Sustained response ¼ normalized pupil diameter between 5 and 7 seconds.
† Patient SMS 5 was not able to complete the examination.
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activation of ipRGCs and therefore might play a role in the PLR
as well.39,40 Although the changes were found only in the
sustained response to the blue flash pointing to a disturbance
of the melanopsin/ipRGC system in SMS patients, further
studies are necessary to investigate the integrity of these
downstream retinal mechanisms in SMS patients.
Other hypothesis is the reduction in the number of ipRGCs
(or the number of active ipRGCs) in the retina of SMS patients.
This condition was previously reported in patients with
glaucoma.41,42 Gracitelli et al.,42 for instance, found a positive
association between ipRGC/melanopsin dysfunction and nerve
fiber layer thickness. However, glaucoma patients showed
changes not only in the sustained response but also in the peak
response of the PLR to blue light and to red light as well. Since
the SMS patients show disturbances only in the sustained
response to blue light, the results are more suggestive of an
alteration of the melanopsin expression or function than to a
decrease in the amount of the ipRGCs.
If melanopsin expression or function is disturbed in SMS
patients, as we propose, one might speculate its possible
cause. One possibility is that it might be related to the genetic
alteration that causes SMS. The alteration of the RAI1 gene,
which plays an important role in the development of the
central nervous system and controls the activity of other genes,
such as the clock genes, is well described in SMS patients.1,2,43
However, evidence of interaction between the RAI1 gene and
the opsin 4 (OPN4, the gene responsible for the melanopsin
expression), or even alteration of the OPN4 itself in SMS
patients, has not been investigated, to our knowledge.
Another possibility that could explain the sustained
response disturbances in SMS patients is a dysfunctional
mechanism of the melanopsin regeneration. It has been shown
that melanopsina can regenerate using external44 and intrinsic
photoregenerative mechanisms.24,45–47 Moreover, PLRs are
affected if regeneration of melanopsin is disturbed.44 Further
investigations might consider phototransduction as well as
photoregenerative mechanisms as a possible cause of mela-
nopsin dysfunction in SMS patients.
The results of the 6-sulfatoxymelatonin in SMS patients
showed impairment in their expected daily melatonin
production profile. These results are consistent with the lack
of photoinhibition, leading, in some cases, to a phase-shifting
in the production of melatonin and in all cases high
circulating levels during the day. It is well known that the
regular daily pattern of melatonin production by the pineal
gland contributes to circadian synchronization in most
vertebrates.48 It is noteworthy that the daily melatonin profile
alteration in SMS patients remains highly reproducible from
day to day in these individuals.49 These abnormalities are
found in the great majority of patients, more than 95% as
shown by Potocki et al.7 (18 out of 19 patients), De
Leersnyder et al.8 (26 out of 27 patients), Nova´kova´ et al.9
(3 out of 5), among others, and is usually associated with
sleep disturbances in these patients.6 In addition, an apparent
abnormal daily profile of clock genes, particularly Per2, has
been recently described in SMS patients.9 However, it should
be stressed that it is not possible to postulate a generalized
circadian rhythm disturbance as a cause of altered melatonin
profile since De Leersnyder et al.8 showed that all SMS-studied
patients, even though there is circadian disruption of
melatonin profile and sleep/wake cycle, presented with no
alteration in the expected circadian pattern of cortisol,
growth hormone, and prolactin secretion or body tempera-
ture.8 Moreover, a putative decline in the robustness of the
circadian clock rhythm, as stated by Nova´kova´ et al.,9 would
explain the phase-shift of melatonin production observed in
SMS patients, but it does not explain why the disturbed
circadian melatonin profile is not photoinhibited by the daily
indoor light or sunlight. As stated by De Leersnyder,4 even
though there is an anomalous melatonin rhythm, it was
reproducible day after day and follows a regular 24-hour
period secretion. This suggests a dysfunction in the phase
relationship between the light/dark environmental cycle and
the circadian clock rather than to a circadian time-generation
dysfunction.4 As stated previously, the retinal ipRGC mela-
nopsin system and its central projections are part of the
neural system controlling the daily melatonin profile and its
synchronization to the light/dark cycle.
The integrity of the ipRGCs/melanopsin system is funda-
mental for sending light information necessary for the
entrainment of circadian melatonin rhythm and for several
other functions of the nonimage-forming visual system. In
addition, it guarantees that via the well-known photoinhibition
phenomenon, the nocturnal melatonin profile is restricted to
and follows the exact duration of the night darkness; it is, in
fact, one of the most stable biological signals to time the
physiological changes necessary for daily and seasonal adapta-
tions.16 The daily nocturnal production of melatonin is a
critical signal for the synchronization of peripheral clocks by
the SCN,49–51 and it is essential for the integrity of the internal
circadian timing system. The daily melatonin signal is
important to time daily sleep/wakefulness,52–54 activity/rest,48
and energy metabolism,55 among several other functions.56–58
Therefore, in addition to a dependent direct genetic mecha-
nism as a likely cause of the alterations observed in SMS,59–61
the consequent disturbed melatonin profile aggravates and
potentiates sleep/wakefulness and behavioral and metabolic
symptoms as seen in SMS patients. As a consequence, the
therapeutic correction of the melatonin profile has been used
to alleviate several of these symptoms, as well as to aid in
proper sleep.4,62,63
In this way, the reduced ipRGC response that we
demonstrated to be present in SMS patients should be
considered one of the pathogenetic components of the well-
described circadian, metabolic, sleep, and daily melatonin
profile disturbances of the Smith-Magenis syndrome.
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